MAIA dosed first patient in THIO-104 Phase 3 trial of ateganosine for third-line NSCLC

MAIA Biotechnology, Inc.

First patient dosed in THIO-104 Phase 3 pivotal trial evaluating ateganosine + CPI vs chemo in third-line NSCLC.
Trial targets up to 300 patients with primary endpoint of overall survival; screening underway in Taiwan, Turkey, EMA countries, Georgia.
CEO Vitoc and board purchased ~182,445 shares on open market Nov 21–28, 2025; insiders now hold 12.95% of company.
Phase 2 data showed median OS 17.8 months vs ~6 months for chemo; FDA granted Fast Track designation for ateganosine.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.